Key result
Novel fluorescent lateral flow test detects serum leptin to address BMI limitations in metabolic syndrome.
Why the study?
BMI measurement has limitations and variable significance across populations for diagnosing obesity and metabolic syndrome, leading to interest in metabolic biomarkers such as adipokines.
Describes the development of a fluorescent lateral flow test for detecting the metabolic biomarker leptin in human serum.
Leptin assay shows promise as metabolic biomarker; leaves open whether it improves obesity diagnosis over BMI.
Body mass index (BMI) measurement is the primary method for diagnosing and classifying obesity and metabolic syndrome, despite limitations and variable significance across populations. Metabolic biomarkers, such as adipokines, offer...
No takes yet. Share an insight, caveat, or question.
Ortiz‐Martínez et al. (2026) studied this question. A fluorescent lateral flow test was developed for the detection of the metabolic biomarker leptin in human serum to address limitations of BMI in diagnosing obesity and metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: